Alpha-Synuclein, E46K mutant-rPeptide Introduces new peptide for Parkinson research

September 24, 2008

Alpha-Synuclein, E46K mutant-rPeptide Introduces new peptide for Parkinson research


MW: 14,459 Da

Description:
Lyophilized powder. Purity >95% by SDS-PAGE and Mass Spec. A point mutantion (E46K) of Alpha-Synuclein gene that has been linked to autosomal dominant early onset Parkinson’s Disease (PD

References:
Zarranz, J.J., et. al. 2004, Ann Neurol. 55, 164

http://www.rpeptide.com/products/product_details_66.html

Company Info:

rPeptide is a biotechnology company located in Athens, Georgia, USA, and is a market leader in providing research products (recombinant peptides and proteins, antibodies, reagents) for Alzheimer’s disease and Parkinson’s disease research. rPeptide also provides a range of custom services from molecular biology, protein expression and purification, to 13C and 15N uniform labeling of peptides and proteins.

rPeptide has a proprietary platform vector technology that enables the expression of historically difficult peptides/proteins as soluble peptides/proteins (like amylin, beta-amyloid, leptin, pro-insulin) in E. coli. For more information, contact:

Sanjay Bhardwaj

4241 Mars Hill Road,

Bogart, GA 30622, USA

Tel: 678-753-0747

Fax: 678-753-0746

sanjayb@rpeptide.com

www.rpeptide.com

Alpha Synuclein-rPeptide Introduces New proteins

July 29, 2008

Alpha Synuclein-rPeptide Introduces New proteins

Summary

Alpha Synuclein, 1-60

Alpha Synuclein, 1-95

Alpha Synuclein, 61-140

Alpha Synuclein, 96-140

Alpha Synuclein, 1-60

MW: 6,149 Da
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-60), which contains the N-terminal amphipathic domain. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinson’s disease aggregates and is implicated in the pathogenesis of Parkinson’s Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinson’s disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinson’s disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimer’s disease.

References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

For more info:

http://www.rpeptide.com/products/product_details_112.html

Alpha Synuclein, 1-95

MW: 9,391 Da

Description:
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 1-95), which contains the N-terminal amphipathic domain and the NAC region. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinson’s disease aggregates and is implicated in the pathogenesis of Parkinson’s Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinson’s disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinson’s disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimer’s disease.

References:
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

For more info:

http://rpeptide.com/products/product_details_113.html

Alpha-Synuclein, 61-140

MW: 8,460 Da

Description:
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-synuclein (amino acids 61-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinson’s disease aggregates and is implicated in the pathogenesis of Parkinson’s Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinson’s disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinson’s disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimer’s disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

For more info:

http://rpeptide.com/products/product_details_114.html

Alpha-Synuclein, 96-140

MW: 5,217 Da

Description:
Lyophilized powder. Purity > 95% by SDS-PAGE; A deletion mutant of Alpha-Synuclein (amino acids 96-140). Additional amino acid (Met) is attached at the N-terminus. Alpha-Synuclein is a 14 kD (140 amino acids) acidic presynaptic protein. It is a major component of Parkinson’s disease aggregates and is implicated in the pathogenesis of Parkinson’s Disease and related neurodegenerative disorders. Alpha-Synuclein accumulates in the brains of sporadic Parkinson’s disease patients as a major component of Lewy bodies, which are intraneuronal cytoplasmic inclusions characteristic of Parkinson’s disease. Alpha-Synuclein appears to associate with other proteins that aggregate and is found in amyloid plaques and neuritic tangles in Alzheimer’s disease.

References:
Park, S. M. et al. (2002) Blood, 100(7) 2506
Park, S. M. et al. (2002) Biochemisty. 41, 4137
Conway, K.A. et. al., (2000) Biochemistry, 39: 2552
Jakes, R. et al. 1994, FEBS Letters, 345, 27
Masliah, E. et. al., 2001. Proc. Natl. Acad. Sci., USA, 98, 12245
Ueda, K., et. al. 1993. Proc. Natl. Acad. Sci., USA, 90, 11282

For more info:

http://rpeptide.com/products/product_details_115.html

Company Info:

rPeptide is a biotechnology company located in Athens, Georgia, USA, and is a market leader in providing research products (recombinant peptides and proteins, antibodies, reagents) for Alzheimer’s disease and Parkinson’s disease research. rPeptide also provides a range of custom services from molecular biology, protein expression and purification, to 13C and 15N uniform labeling of peptides and proteins.

rPeptide has a proprietary platform vector technology that enables the expression of historically difficult peptides/proteins as soluble peptides/proteins (like amylin, beta-amyloid, leptin, pro-insulin) in E. coli. For more information, contact:

Sanjay Bhardwaj

4241 Mars Hill Road,

Bogart, GA 30622, USA

Tel: 678-753-0747

Fax: 678-753-0746

sanjayb@rpeptide.com

www.rpeptide.com


Follow

Get every new post delivered to your Inbox.